Uterine corpus diffuse leiomyomatosis
diseaseOn this page
Also known as body of uterus leiomyomatosisleiomyomatosis of body of uterusuterine corpus leiomyomatosis
Summary
Uterine corpus diffuse leiomyomatosis (MONDO:0003704) is a disease. A subtype of leiomyomatosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | uterine corpus diffuse leiomyomatosis |
| Mondo ID | MONDO:0003704 |
| DOID | DOID:5916, DOID:5917 |
| NCIT | C40170 |
| UMLS | C1519855 |
| MedGen | 275556 |
| GARD | 0023624 |
| Anatomy (UBERON) | UBERON:0009853 |
| Is cancer (heuristic) | no |
Also known as: body of uterus leiomyomatosis · leiomyomatosis of body of uterus · uterine corpus diffuse leiomyomatosis · uterine corpus leiomyomatosis
Disease family
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign muscle neoplasm › benign smooth muscle neoplasm › leiomyoma › leiomyomatosis › uterine corpus diffuse leiomyomatosis
Related subtypes (2): intravenous leiomyomatosis, disseminated peritoneal leiomyomatosis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.